Aclasta 5 mg solution for infusion

DRUG4 trials

Sponsors

Ultragenyx Pharmaceutical Inc., Aarhus University Hospital, Oslo University Hospital HF, Azienda Ospedaliera Universitaria Integrata Verona

Conditions

Erosive hand osteoarthritis (EHOA)Low Back Painosteogenesis imperfectaosteoporosis

Phase 2

Denosumab or Zoledronic acid for erosive hand osteoarthritis (EHOA) in patients with osteoporosis a randomized controlled trial (ZODIAC trial)

Not yet recruitingCTIS2026-526828-41-00

Azienda Ospedaliera Universitaria Integrata VeronaErosive hand osteoarthritis (EHOA)

Target: 150Updated: 2026-08-14

Phase 3

The Optimised use of Romosozumab Study

RecruitingCTIS2023-505940-20-00

Aarhus University Hospitalosteoporosis

Start: 2023-09-26Target: 270Updated: 2025-05-10

An Open-label, Randomized, Active-Controlled, Phase 3 Study of Setrusumab Compared With Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta Types I, III or IV

Active, not recruitingCTIS2023-504196-24-00

Ultragenyx Pharmaceutical Inc.osteogenesis imperfecta

Start: 2023-10-17Target: 27Updated: 2025-11-13

ZAMBA: Zoledronic Acid for Modic Back Pain. A randomized, double blind, placebo-controlled, multicenter trial

Not yet recruitingCTIS2024-517345-14-00

Oslo University Hospital HFLow Back Pain

Target: 118Updated: 2025-10-30